Neoadjuvant Immunotherapy Plus CRT Versus Neoadjuvant CRT for Locally Advanced Resectable ESCC

Key facts

Sponsor

Shanghai Zhongshan Hospital

Principal Investigator

Lijie Tan, MD

Shanghai Zhongshan Hospital

Intervention

Neoadjuvant Chemoradiotherapy(procedure)

Enrollment

176 enrolled

Eligibility

18-75 years · All sexes

Timeline

2022 – 2027

Study locations (1)

• Shanghai Zhongshan Hospital, Shanghai, China

Collaborators

Peking University Cancer Hospital & Institute · Shanghai Chest Hospital · First Affiliated Hospital of Wenzhou Medical University · Tianjin Medical University Cancer Institute and Hospital · Ningbo Medical Center Lihuili Hospital · The First People's Hospital of Changzhou · Zhongshan Hospital (Xiamen), Fudan University · Xuhui Central Hospital, Shanghai · Shanghai Minhang Central Hospital · Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Zhejiang Cancer Hospital · Sichuan Cancer Hospital and Research Institute · Tongji Hospital · Sun Yat-sen University · Shanghai Fifth People's Hospital

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Squamous cell carcinoma of the esophagus

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT07457528
  Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCC
  Tianjin Medical University Cancer Institute and Hospital
• RECRUITINGPHASE2NCT07331155
  A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)]
  Nanjing Leads Biolabs Co.,Ltd
• RECRUITINGPHASE1NCT07503808
  A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
  IDEAYA Biosciences
• RECRUITINGPHASE2NCT07403136
  Vebrekotuzumab ± Anti-PD-1 in Pretreated Advanced ESCC
  Fudan University
• RECRUITINGPHASE1, PHASE2NCT07385001
  A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as Neoadjuvant Therapy for ESCC
  Tang-Du Hospital
• RECRUITINGPHASE2NCT07263919
  Perioperative Cadonilimab Combined With Neoadjuvant Chemotherapy in Resectable Esophageal Squamous Cell Carcinoma (ESCC)
  Akeso
• RECRUITINGPHASE2NCT07481058
  KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer
  Beijing Konruns Pharmaceutical Co., Ltd.
• RECRUITINGPHASE1NCT07217171
  A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
  EvolveImmune United, Inc

See all trials for Squamous cell carcinoma of the esophagus →